1. Most Medicare patients were likely to complete the multitarget stool DNA test Cologuard over a yearlong period, according to a study published in the Journal of Medical Screening. Read more here.
2. Exact Sciences posted fourth-quarter 2019 revenues of $295.6 million and full-year revenues of $876.3 million. Read more about the company’s earnings here.
3. About 1.68 million Cologuard tests were completed in 2019, an 80 percent year-over-year increase.
4. In 2020, Exact Sciences said it plans to target the 45-49 age group. Exact Sciences CEO and chairman Kevin Conroy said the company will “[enhance] our marketing efforts and [work] to raise awareness of the need for earlier screening. We also plan to publish results from our prospective study in the 45- to 49-year-old age group this year to further support Cologuard use.”
5. The company expects to post revenues of $1.61 billion to $1.645 billion this year, with Cologuard screening revenues surpassing $1 billion for the first time.
More articles on gastroenterology:
Takeda to acquire PvP Biologics after celiac treatment study concludes
Why GI is still ripe for PE investment
3 new gastroenterology-focused ASCs, facilities opened or announced this month
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
